Global Lidocaine Ointment Market: Key Developments
In April 2022, Alembic Pharmaceuticals Limited, a pharmaceutical company, announced that its subsidiary Aleor Dermaceuticals Limited had received final approval from the U.S. Food and Drug Administration (USFDA) Abbreviated Marketing Authorization Application (ANDA) Lidocaine and Prilocaine Cream USP, 2.5%. Lidocaine is indicated as a local anesthetic for use on normal intact skin for topical analgesia and genital mucosa as a pretreatment for superficial minor interventions and infiltration anesthesia.
Lidocaine Ointment Market Report Snapshots
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients